Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival-Reference-Cited by-同舟云学术

Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival

Published:1985-11 Issue:5 Volume:23 Page:833-841
ISSN:0022-4731
Container-title:Journal of Steroid Biochemistry
language:en
Short-container-title:Journal of Steroid Biochemistry

Author:

Labrie F.,Dupont A.,Belanger A.,Giguere M.,Lacoursiere Y.,Emond J.,Monfette G.,Bergeron V.

Publisher

Elsevier BV

Subject

Endocrinology,Biochemistry

Reference33 articles.

1. Epidemiologic observations from the American College of Surgeon's Survey on prostate cancer;Mettlin;Prostate,1983

2. A new approach in the hormonal treatment of prostate cancer: complete instead of partial blockade of androgens;Labrie;Int. J. Androl.,1984

3. Treatment of advanced carcinoma of the prostate;Williams;Br. med. J.,1984

4. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone;Murphy;Cancer,1983

5. Studies of prostatic cancer;Huggins;I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the lorostate. Cancer Res,1941

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy;Cancers;2022-12-15

2. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer;Frontiers in Endocrinology;2022-10-03

3. High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice;iScience;2022-05

4. Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?;Cancers;2021-12-21

5. Kombinierte Systemtherapie beim metastasierten hormonsensitiven Prostatakarzinom: Was? Wann? Bei wem?;Der Urologe;2020-04-09